Product Launch

Advanced Medical Solutions Grp PLC
6 December 2001


For Immediate Release:                        07.00 am Thursday 6 December 2001



        Advanced Medical Solutions Group plc ('AMS' or the 'Company')



                 Agreement with Novartis Consumer Health SA
              to launch a new scar reduction dressing into Spain



Winsford, UK: AMS, the medical device company, has today announced the launch,
into the Spanish market, of 'Trofolastin(R) Scar Reduction' in association
with Novartis Consumer Health SA.  Trofolastin(R) is an anti-stretch-mark
cream developed and marketed in Spain by Novartis, which is recommended by
many Spanish nurses and physicians, while Trofolastin Scar Reduction is a
proprietary dressing for the treatment of scars.  The agreement gives Novartis
the exclusive rights for the product in this territory.



The new dressing, which has been developed by AMS and is based on the
Company's  patented polyurethane membrane technology, helps reduce scarring by
flattening scar tissue and reducing redness.



'We are pleased to enter into this relationship with AMS and to add this
unique product to our highly successful Trofolastin(R) range,' said Michel
Gardet, General Manager of Novartis Consumer Health in Spain. 'We see an
exciting opportunity for use of this product on scars, particularly following
caesarean sections.'



AMS already supplies a range of advanced wound care products to Novartis
Consumer Health Europe under brand names such as Savlon(R) in the UK, Fenistil
(R) in Germany and Merfen(R) in Switzerland.



Chief Executive Officer of AMS, Don Evans, commented:  'We are pleased to
extend our relationship with Novartis Consumer Health to include Spain - this
is a very interesting market for the initial launch of our new scar reduction
dressing.  We look forward to rolling it out into additional territories
during 2002 as either a new launch or to upgrade existing products.'



Referring to general trading within AMS, Dr Evans added:



'This launch continues our strategy of developing major partnerships while
actively moving our Consumer business away from the highly competitive and
price sensitive grocery end of the market towards higher value advanced wound
care products sold through pharmacies.  Whilst this strategy has restricted
the sales growth in our Consumer business in the current year, it has improved
the quality of those sales and allowed for a more effective leveraging of the
technology employed in our professional wound care business, which continues
to grow strongly.  We approach the end of the year with trading in line with
market expectations for both profitability and cash.



In addition our recent announcement concerning the grant of a patent for an
anti-bleeding gel, has attracted much interest, particularly for
anti-bacterial haemostatic products. We are currently in the process of
assessing potential licensing partners for such a product.'



                                   - ENDS -

For further information, please contact:


Advanced Medical Solutions Group plc           Tel: [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com


Buchanan Communications                               Tel: [phone]
Nicola How / Fergus Mellon





Notes to Editors:

Novartis is a world leader in healthcare with core businesses in
pharmaceuticals, consumer health, generics, eye-care, and animal health and
operates in over 140 countries around the world. Headquartered in Nyon,
Switzerland, the Consumer Health division manufactures, develops and markets a
wide range of branded products, the purpose of which is to restore, maintain
or improve consumer health.



Advanced Medical Solutions is a leading global company in the development and
manufacture of products for the advanced wound care market.  This is currently
estimated to be in excess of £1 billion world-wide (2000).



Funded in 1991 and floated on the Full List of the London Stock Exchange in
1996, Advanced Medical Solutions is focused on the design, development and
manufacture of innovative and technologically advanced products for wound care
and other medical applications.



In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.



AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast and Smith + Nephew / Beiersdorf.



In addition to the Professional and Consumer Woundcare divisions, AMS has
established a Research & Technology Division.  This was set up in 1999 to ring
fence technical expertise to develop technology platforms for the future. The
key focus of Research & Technology is to develop new material and device
technologies for commercialisation.